Open AccessP1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE‐ARM MULTICENTER PHASE 2 CLINICAL TRIAL
Author(s) -
wang T.,
sun X.,
qiu L.,
su H.,
cao J.,
li Z.,
song Y.,
zhang L.,
yi S.,
qiu L.,
zhou J.,
wu H.,
zhang W.,
li J.,
zhou K.,
zhou H.,
yang Y.,
li Z.,
cen H.,
cai Z.,
zhang Z.,
fu W.,
jin J.,
li F.,
wu W.,
gu X.,
zhu W.,
liu L.,
li Z.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847344.35314.45
Subject(s) - medicine , refractory (planetary science) , gastroenterology , follicular lymphoma , phases of clinical research , progression free survival , lymphoma , adverse effect , clinical trial , surgery , chemotherapy , astrobiology , physics